ICOS and metastatic melanoma: Nevertheless, strategies for the clinical development of ICOS agonist mAbs should closely evaluate the basal differences in T-cell subtypes and functional status across indications of interest, in particular tumor types known to exhibit innate or therapy-induced priming of antitumor immunity, such as HNSCC and metastatic melanoma, respectively.